Healthtronics — Investor Presentation (January 2006)
39 slides from Healthtronics's investor presentation, Jan 17, 2006
Slide 1: HealthTronics, Inc. January 2006
HealthTronics, Inc. January 2006 Exhibit 99.1
Slide 2: Forward-looking statements
HealthTronics 2 Statements in this presentation that are not strictly historical, including statements regarding plans, objective and future financial performance, are “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
Slide 3: Business Segments/Sub-Segments
HealthTronics 3 Business Segments/Sub-Segments ~ Urology Services • Lithotripsy • Prostate Therapies • Anatomical Pathology ~ Medical Devices • Sales • Service ~ Specialty Vehicles • Medical • Broadcast • Homeland Security
Slide 4: Urology Services
HealthTronics 4 UROLOGY SERVICES - Lithotripsy - Prostate Therapies - Uropathology
Slide 5: Leading Competitive Position
HealthTronics 5 Leading Competitive Position ~ Partnering with 1/3 of Nation’s Urologists ~ Veteran Management Team ~ Bringing Cutting-edge Therapies to Market ~ Successful Partnership Model ~ Proven Execution
Slide 6: Core Objectives
HealthTronics 6 Core Objectives ~ Leverage Urology Channel • Trusted Advisor to our Partners • Value-added Products and Services ~ Facilitate Marketplace Consolidation • Growing Revenue & Taking Share • Expanding Platform ~ Expand Margins • Pricing Stability • Wholesale Pricing Power • Operating Eff
Slide 7: Lithotripsy
HealthTronics 7 Lithotripsy ~ Cost Effective, Non-invasive, Efficacious • Fractional Cost of Surgical Alternatives ~ Market Scope • 250,000 Cases per Year • $2,000 per Case Revenue • $500M Revenue Market ~ Physician-driven Therapy ~ No Alternative Therapy ~ 93 Partnerships in 47 states ~ 183 install
Slide 8: Lithotripsy Partnership Economics
HealthTronics 8 Lithotripsy PARTNERSHIP ECONOMICS Sale of Equipment Equipment & Consumables Management 35% 65% Partnership Distributions Long Term Partnerships Non-Competes Lithotripsy Partnership Doctors (LPs) Reimbursement for Procedure HealthTronics (GP) Maintenance $ $ $ $
Slide 9: Prostate Therapy – BPH
HealthTronics 9 Prostate Therapy – BPH ~ Benign Prostatic Hyperplasia • Non-cancerous Enlargement of the Prostate ~ Market Scope • Affects 50% of Men Over Age 60 • 13 Million American Men in 2004 • Growth Rate – From 40,000 to 360,000 Minimally Invasive Treatments • $650 Million - $700 Million Marke
Slide 10: Prostate Therapy – Prostate Cancer
HealthTronics 10 Prostate Therapy – Prostate Cancer ~ Market Scope • Second Most Common Cancer in American Males – 230,000 New Cases per Year in the U.S. – Baby Boomer Impact (approximately 40 million males) • $5B market ~ Dramatic Increase in Public Awareness • Demanding Focal Therapy vs. Total Abl
Slide 11: Prostate Cancer Treatment Alternatives
HealthTronics 11 Prostate Therapy – Prostate Cancer ~ Treatment Alternatives • Total Ablation – Radical Surgery – Radiation (beam) • Focal Therapies – Cryotherapy (freeze) • Other – Brachytherapy (seeds) – HIFU # of US Procedures % of Total 120,000 48% 59,000 24% 6,000 2% 64,000 26% N/A* N/A * Appro
Slide 12: Uropathology Market
HealthTronics 12 ~ Market is Approximately $500 Million ~ 8,400 Private Practice Urologists • Approximately 10 Prostate Biopsies / Month ~ Each Patient = Approximately $600 Revenue ~ 60% of Patients are Medicare ~ Medicare Reimbursement is Excellent Uropathology Market
Slide 13: Focal Diagnosis to complement Focal Therapies
HealthTronics 13 ~ Focal Diagnosis to compliment Focal Therapies ~ Timeliness & Accuracy – Turnaround Within 48 Hours ~ Technology – Electronic Reporting ~ Customer Service – Physician Oriented Pathologists HealthTronics Uropath Advantage – Big Lab Technology, Small Lab Service
Slide 14: Development Strategy: Beta Users
HealthTronics 14 ~ Beta Users • HTRN Physician Partners ~ Beta Sites • Georgia, Louisiana & Mississippi ~ Investment • 2005 CapEx $2 Million Development Strategy
Slide 15: Medical Device Sales & Service
HealthTronics 15 MEDICAL DEVICE SALES & SERVICE
Slide 16: Devices: Lithotripters
HealthTronics 16 Devices ~ Lithotripters • Market Scope : – Total US Installed Base of 650 Units – Average Selling Price of $390,000 – 35% of US Market is Spark Gap Technology – US HTRN Manufactured Installed Base of 220 Units • Opportunities : – Dual Branding Strategy to Expand Spark Gap Market – N
Slide 17: HTRN New Urology Imaging System
HealthTronics 17 HTRN New Urology Imaging System UroVantage
Slide 18: Devices: Urology Imaging System
HealthTronics 18 Devices ~ Urology Imaging System • Market Scope : – Total US Installed Base of 4,500 Units – 200 - 250 Units Purchased in US Annually at $300,000 ASP – Urologist Influential in Equipment Decision – Market Moving Toward Multi-Specialty Surgical Units • Opportunities : – UroVantage la
Slide 19: Devices: Other Products
HealthTronics 19 Devices ~ Other Products • Patient Management Tables: – US Installed Base of 4000 Units, HTRN 450 Units Installed – Comprehensive Dealer Network, OEM Supplier • PSA Testing: – 6 Million PSA Tests Performed Annually, $200 Million Market – In-Office Testing Approved and now Reimbursed
Slide 20: Service Engineering
HealthTronics 20 Service Engineering ~ Installed Base/Network : • Currently Service 38% of US Lithotripter Installed Base • 180 of 250 Total HTRN Service Base is Within Partnerships • 36 Field Engineers Trained in Lithotripsy and X-Ray • 530 Units Generating Consumable Revenue ~ Opportunities : • IS
Slide 21: Specialty Vehicle Manufacturing
HealthTronics 21 SPECIALTY VEHICLE MANUFACTURING
Slide 22: Sales process for Specialty Vehicles division
HealthTronics 22 ~ Company is currently interviewing investment bankers to manage a sales process for this division. ~ Estimated value is $100 - $115 million SPECIALTY VEHICLE MANUFACTURING
Slide 23: Specialty Vehicle Manufacturing
HealthTronics 23 SPECIALTY VEHICLE MANUFACTURING AK Specialty Vehicles is Global Leader in the Design, Engineering and Construction of Specialty Vehicles. Medical Imaging Broadcast & Communications Command/Homeland Security
Slide 24: Leadership Position in Mobile Medical Worldwide
HealthTronics 24 Leadership Position in Mobile Medical Worldwide ~ Manufacturing Facilities in U.S. and Europe ~ Strategic Relationships for all Modalities • GE Healthcare Technologies • Philips Medical Systems • Siemens Medical Solutions ~ Extraordinary Market Breadth • Australia • Finland • Korea
Slide 25: Leadership Position in Broadcast & Communications Vehicles
HealthTronics 25 Leadership Position in Broadcast & Communications Vehicles Worldwide ~ Strong Customer Base • Major Networks - ABC, CBS, FOX, NBC • Cable Networks - CNN, Time Warner • Satellite Uplink Service Market – Relay House, PSSI, Calhoun, Arctek, Coastal, STS • Export Market – Canada, Morocc
Slide 26: Homeland Security
HealthTronics 26 Homeland Security
Slide 27: Mobile Command Center
HealthTronics 27 Mobile Command Center Mobile Command Center Homeland Security Market Breadth : ~ Mobile Communications Centers ~ First Responder Units ~ Mobile Emergency Ops Units ~ Military Training Simulators ~ Tactical transport
Slide 28: Homeland Security Federal Funding Programs
HealthTronics 28 Homeland Security ~ Federal Funding Programs ~ $2.6B In Federal Funds are Allocated for 2005 : • Urban Area Security Initiative Grant – Earmarked for Top 50 Metropolitan Areas • State Homeland Security Grant – States/Municipalities Response Capabilities ~ 2005 Programs Initiated by
Slide 29: Conclusion
HealthTronics 29 Conclusion • Market Dominator • Hi Barriers to Entry • “Debt-Free” Segment • Focused, Stand Alone Business Unit
Slide 30: 2006 Financial Forecast
HealthTronics 30 2006 FINANCIAL FORECAST
Slide 31: Segment Summary Income Statement
HealthTronics 31 Segment Summary Income Statement 2006 Forecast ($ in millions) Urology Medical Devices Specialty Vehicles Revenues $157 $20 (2) $120 EBITDA $82 $10 $15 Adjusted EBITDA (1) $33 $10 $15 (1) EBITDA less minority interest (2) After inter-company eliminations
Slide 32: Key Financial Statistics
HealthTronics 32 Key Financial Statistics ($ in millions) 2006 Forecast 12/31/06 Total Debt $112 Cash (24) Net Debt $88 Ratios: Funded Debt to EBITDA 2.14x A/R Days Sales Outstanding 37.0 Interest Coverage (Adjusted EBITDA/Interest Expense) 6.5x Net Working Capital $75
Slide 33: 2006 Forecast Pro Forma Free-Cash Flow
HealthTronics 33 2006 Forecast Pro Forma Free-Cash Flow For the Year 2006 Adjusted EBITDA $52.0 Interest Expense (8.0) Income Tax Expense (12.0) Cap X, Net (4.5) $27.5
Slide 34: Consolidated Summary Income Statement
HealthTronics 34 Consolidated Summary Income Statement ($ in millions) 2006 Forecast Revenues $297 Adjusted EBITDA $52 EPS $0.52 - $0.55
Slide 35: Implementation of Strategic Initiatives
HealthTronics 35 Implementation of Strategic Iniatives 1. Proceed with FDA approval for HIFU 2. Introduce Urology Imaging System 3. Establish UroPathology Capability (early 2006) 4. Focus on strategic acquisition targets 5. Divest Specialty Vehicles Division
Slide 36: Reconciliation of EBITDA and Adjusted EBITDA
HealthTronics 36 Reconciliation of EBITDA and Adjusted EBITDA ($ in millions) Combined Operations Net Income $ Add Back(deduct): Provision for income taxes Interest Expense, Including Loan Fees Depreciation & Amortization Adjusted EBITDA Add Back: Minority Interest Expense EBITDA $
Slide 37: Reconciliation of EBITDA and Adjusted EBITDA
HealthTronics 37 Reconciliation of EBITDA and Adjusted EBITDA ($ in millions) Urology Medical Device Specialty Vehicles Income before taxes $ $ $ Add Back(deduct): Interest Expense, Including Loan Fees - - Depreciation & Amortization Adjusted EBITDA Add Back: Minority Interest Expense - - EBITDA $ $
Slide 38: HealthTronics non-GAAP measures
HealthTronics 38 HealthTronics has presented EBITDA and Adjusted EBITDA amounts, which are non-GAAP financial measures, in various filings with the SEC. In the SEC filings, HealthTronics has reconciled such amounts to their most directly comparable financial measure calculated in accordance with GAA
Slide 39: Use of EBITDA and Adjusted EBITDA
HealthTronics 39 EBITDA and Adjusted EBITDA are used in addition to and in conjunction with results presented in accordance with GAAP. EBITDA and Adjusted EBITDA should not be considered as an alternative to net income, operating income, a liquidity measure, or any other operating performance measur